How to improve the efficacy and reverse the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, remains a major challenge in the targeted therapy of lung adenocarcinoma with EGFR-activating mutation. Phosphoglycerate dehydrogenase (PHGDH) is the key enzyme of de novo serine biosynthesis over-expressed in various types of cancer including lung cancer. Elevated PHGDH expression is correlated with a worse overall survival in clinical lung adenocarcinoma patients. Here we investigated the role of PHGDH in lung adenocarcinoma with the acquisition of resistance to erlotinib.

中文翻译：

---

通过抑制磷酸甘油酸脱氢酶克服EGFR突变阳性肺腺癌的厄洛替尼耐药性

如何提高疗效并逆转对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）（例如埃洛替尼）的抵抗，仍然是靶向治疗具有EGFR激活突变的肺腺癌的主要挑战。磷酸甘油酸脱氢酶（PHGDH）是在各种类型的癌症（包括肺癌）中过表达的从头丝氨酸生物合成的关键酶。在临床肺腺癌患者中，PHGDH表达升高与总体生存期较差有关。在这里，我们研究了PHGDH在肺腺癌中的作用以及对埃洛替尼的耐药性。